Additionally, while our past research has linked tumor GDF-15 expression to nivolumab response in NSCLC [20], the findings of the current trial emphasize the clinical importance of serum GDF-15 as a dynamic biomarker reflecting individual patient characteristics. This evidence concerns the gene GDF15 and neoplasm.